Abstract 324: PF-08052666 (SGN-MesoC2; HBM9033), a first-in-class topoisomerase 1 inhibitor-based ADC targeting MSLN, demonstrates potent antitumor activity in preclinical models of ovarian, lung, and colorectal cancers
Year: 2025
Type: conference-abstract
Source: Cancer Research
Authors: Garrett L. Cornelison, Meihong Zhang, Cui Nie, Guangbei Zhu
Institution: Pfizer (United States)
Language: English
Subfield: Radiology, Nuclear Medicine and Imaging
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W4409691071